Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871901 | 0.77 | MAOB (0.33) | NPC1RAB9AABCG2 | |
| SCHEMBL5871995 | 0.75 | NPC1 (0.36) | KDM4ENPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL17289116 | 0.68 | — | — | |
| SCHEMBL7047825 | 0.65 | CYP3A4 (0.35) | KDM4ENPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL510552 | 0.64 | MAPT (0.30) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL349707 | 0.64 | — | — | |
| SCHEMBL30968 | 0.64 | ALDH1A1 (0.55) | KDM4ENPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL30452062 | 0.64 | ALDH1A1 (0.55) | KDM4ENPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL16369469 | 0.62 | CYP19A1 (0.46) | KDM4ENPC1ALDH1A1MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL8764874 | 0.62 | ALDH1A1 (0.53) | KDM4ENPC1ALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1121129-B1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND ASSOCIATED COMBINATIONS | BRISTOL MYERS SQUIBB CO (US) | 2008-09-03 | — | — | EP | claimed |
| EP-1032393-B1 | QUINOLINE-CONTAINING ALPHA-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON INC (US) | 2006-08-09 | — | — | EP | claimed |
| US-20040229807-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-11-18 | — | — | US | claimed |
| EP-1449835-A2 | Alpha-substituted pyrimidine-thioalkyl and alkylether compounds | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-25 | — | — | EP | claimed |
| EP-1121129-A4 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL MYERS SQUIBB CO (US) | 2002-10-16 | — | — | EP | claimed |
| EP-1247804-A1 | Pyrimidine-thioalkyl and alkylether compounds | PHARMACIA & UPJOHN COMPANY (US) | 2002-10-09 | — | — | EP | claimed |
| EP-1113801-A4 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL MYERS SQUIBB CO (US) | 2002-10-02 | — | — | EP | claimed |
| JP-2002524518-A | — | — | 2002-08-06 | — | — | JP | claimed |
| JP-2002524517-A | — | — | 2002-08-06 | — | — | JP | claimed |
| US-20020035064-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-21 | — | — | US | claimed |
| US-6043248-A | VIRICIDES FOR TREATING AN INDIVIDUAL INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-28 | — | — | US | claimed |
| WO-2000015230-A1 | METHOD FOR TREATING ATHEROSCLEROSIS EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
| WO-2000015229-A1 | METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-03-23 | — | — | WO | claimed |
| US-5981537-A | USEFUL IN THE TREATMENT OF INDIVIDUALS WHO ARE HIV POSITIVE | PHARMACIA & UPJOHN COMPANY (US) | 1999-11-09 | — | — | US | claimed |
| WO-1999019304-A9 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | UPJOHN CO (US) | 1999-07-08 | — | — | WO | claimed |
| WO-1999019304-A2 | ALPHA-ALKYLTHIO SUBSTITUTED PYRIMIDINE ETHERS AND THIOETHERS AS VIRAL REVERSE TRANSCRIPTASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-04-22 | — | — | WO | claimed |
| EP-0824524-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1998-02-25 | — | — | EP | claimed |
| WO-1996035678-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1996-11-14 | — | — | WO | claimed |
| EP-0728130-A1 | PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 1996-08-28 | — | — | EP | claimed |
| WO-1995013267-A1 | PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS | THE UPJOHN COMPANY (US) | 1995-05-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035064-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | SREBF2, SREBF1, AP2A2 | KDM4E 3592/4885NPC1 145/4885ALDH1A1 4196/4885 |
| US-20040229807-A1 | Method for treating atherosclerosis employing an aP2 inhibitor and combination | SREBF2, SREBF1, AP2A2 | KDM4E 3592/4885NPC1 145/4885ALDH1A1 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.